

7th April 2016

Announcements
National Stock Exchange of Australia
PO Box 283
NEWCASTLE NSW 2300

Market Announcement – Extension of Private Placement Closing Date

iQN Ltd (NSX:IQN) (the Company) advises that the Directors have resolved to extend the closing date of the Company's placement of shares to sophisticated and professional investors announced on 9 October 2015 to raise up to \$5,000,000 (the Offer).

The closing date under the Offer will be extended until 30 September 2016.

For and on behalf of the Board.



Kelvin Boateng
Company Secretary
iQnovate Ltd

Sydney: Level 7, 222 Clarence Street, Sydney, NSW 2000, Australia • Phone: +61 2 8239 5400
New York: 400 Madison Avenue, Suite 10A, New York City NY10017 USA | +1 212 433 2630
London: 20 Broadwick Street, London, W1F-8HT, UK • Phone: +44(0)2077121508

Safe Harbor Statement

Any statements in this announcement that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with iQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE iQnovate Ltd

iQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, iQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

iQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.